# Sovleplenib PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/sovleplenib

> Sovleplenib, sponsored by HUTCHMED (China) Ltd (HCM): 5 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | sovleplenib |
| Codes | HMPL-523 |
| Sponsor | HUTCHMED (China) Ltd (HCM) https://sec-api.dev/companies/hcm/catalysts |
| Indications | waiha in china, [Primary Immune Thrombocytopenia (ITP)](https://sec-api.dev/indications/primary-immune-thrombocytopenia-itp) |
| Modality | small_molecule |
| FDA designations | breakthrough, orphan, priority review |

## Timeline

### Mar 2024: trial start

- Status: completed. Date confidence: month. Stage: 3. Indication: wAIHA in China.
- First seen 2025-03-19, last confirmed 2026-03-05.
- SEC Form 10-K (accession 0001104659-26-023822): "In March 2024, we initiated the Phase III registration part of the Phase II/III clinical trial of sovleplenib in adult patients with wAIHA in China." https://www.sec.gov/Archives/edgar/data/1648257/000110465926023822/hcm-20251231x20f.htm
- SEC Form 10-K (accession 0001410578-25-000377): "In March 2024, we initiated the registration stage of the Phase II/III clinical trial (same NCT05535933) of sovleplenib in adult patients with wAIHA in China." https://www.sec.gov/Archives/edgar/data/1648257/000141057825000377/hcm-20241231x20f.htm

### May 16, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Primary Immune Thrombocytopenia (ITP).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05029635 (Phase III Study on HMPL-523 for Treatment of ITP): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-16 (ACTUAL); Lead Sponsor Hutchmed." https://clinicaltrials.gov/study/NCT05029635

### Jan 2026: topline data readout

- Status: completed, met. Date confidence: month. Stage: 3.
- First seen 2026-03-05, last confirmed 2026-03-05.
- SEC Form 10-K (accession 0001104659-26-023822): "In the positive topline results announced in January 2026, the Phase III registration part met its primary endpoint of durable Hb response rate within weeks 5 to 24 of treatment." https://www.sec.gov/Archives/edgar/data/1648257/000110465926023822/hcm-20251231x20f.htm

### 1H 2026: NDA/BLA submission

- Status: scheduled. Date confidence: half.
- First seen 2026-01-07, last confirmed 2026-01-07.
- Press release filed with the SEC (EX-99) (accession 0001648257-26-000004): "HUTCHMED plans to submit the New Drug Application ("NDA") for sovleplenib for wAIHA to the China National Medical Products Administration (NMPA) in the first half of 2026." https://www.sec.gov/Archives/edgar/data/1648257/000164825726000004/hcm-20260107xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001648257-26-000004): "An NDA resubmission for sovleplenib for second-line ITP is planned in the first half of 2026." https://www.sec.gov/Archives/edgar/data/1648257/000164825726000004/hcm-20260107xex99d1.htm

### Feb 2026: NDA/BLA submission

- Status: completed. Date confidence: month.
- First seen 2026-03-05, last confirmed 2026-07-30.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-088458): "NMPA accepted resubmitted NDA filing with priority review status and Breakthrough Designation for 2L ITP in February 2026, with additional data rolling in during the second half of 2026." https://www.sec.gov/Archives/edgar/data/1648257/000110465926088458/hcm-20260730xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001648257-26-000039): "The NMPA accepted for review the resubmitted NDA filing for the treatment of ITP and granted it priority review in February 2026." https://www.sec.gov/Archives/edgar/data/1648257/000164825726000039/hcm-20260612xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001648257-26-000026): "The NMPA accepted for review the resubmitted NDA filing for the treatment of ITP and granted it priority review in February 2026." https://www.sec.gov/Archives/edgar/data/1648257/000164825726000026/hcm-20260429xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-023831): "NMPA accepted our resubmitted NDA filing for 2L ITP in February 2026, with additional data rolling in during the second half of 2026." https://www.sec.gov/Archives/edgar/data/1648257/000110465926023831/tm2525075d2_ex99-1.htm

## Same indication

- [Efgartigimod iv](https://sec-api.dev/pdufa/efgartigimod-iv) (ARGX)
- [Ianalumab](https://sec-api.dev/pdufa/ianalumab) (NVS)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/sovleplenib.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Sovleplenib PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/sovleplenib

```bibtex
@misc{secapidev_pdufa_sovleplenib_20261116,
  title        = {Sovleplenib PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/sovleplenib}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_sovleplenib_20261116","title":"Sovleplenib PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/sovleplenib","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
